STOCK TITAN

Perrigo Co Plc - PRGO STOCK NEWS

Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.

Perrigo Company Plc (NYSE: PRGO) is a global provider of quality, affordable self-care products and over-the-counter health solutions. This dedicated news hub offers investors and industry professionals centralized access to official announcements, financial disclosures, and market developments.

Track Perrigo's strategic initiatives through verified press releases covering earnings results, product innovations, regulatory milestones, and partnership announcements. Our curated collection provides essential insights into the company's operations across key markets in North America, Europe, and global consumer health sectors.

Discover updates on Perrigo's store-brand leadership, branded OTC developments, and manufacturing advancements. The resource serves as a reliable reference for monitoring the company's progress in delivering accessible healthcare solutions through major retail partnerships and direct-to-consumer channels.

Bookmark this page for streamlined access to Perrigo's latest business updates, including analysis of market positioning in consumer self-care categories and operational efficiency programs. Stay informed about one of the OTC sector's most established innovators through verified, up-to-date information sources.

Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Patrick Lockwood-Taylor, and CFO Eduardo Bezerra will participate in investor meetings at the Jefferies Consumer Conference on November 15th, 2023, and present at the Morgan Stanley Consumer & Retail Conference on December 6th, 2023. Interested parties can access the webcast on the Perrigo website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
-
Rhea-AI Summary
Perrigo Company plc plans to issue its Q3 2023 financial results on November 7, 2023, and will host a conference call. The call will be available live via webcast or by phone. A taped replay of the call will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
News
Rhea-AI Summary
Perrigo appoints Catherine Schmelter as EVP and President, Consumer Self-Care Americas and Global Portfolio Optimization. Schmelter to lead strategic direction, growth, and profitability of CSCA business and oversee global portfolio evolution process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
Rhea-AI Summary
Perrigo Company announces participation in investor meetings and conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
-
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) reported second quarter net sales of $1.2 billion, a 6.4% increase compared to the prior year quarter. The company achieved gross and operating margin expansion and delivered strong operating income and EPS growth. The reported gross margin was 35.9%, a 270 basis points improvement, and the adjusted gross margin was 38.7%, a 220 basis points improvement. Reported EPS was $0.06, compared to a loss of $(0.48) in the prior year quarter. Adjusted diluted EPS was $0.63, a 46.5% increase. Perrigo reaffirms its fiscal 2023 outlook with organic net sales growth of 3.0%-6.0% and total net sales growth of 7.0%-11.0%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
-
News
Rhea-AI Summary
Perrigo Company plc announces a quarterly dividend of $0.273 per share payable on September 19, 2023, to shareholders of record on September 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
dividends
Rhea-AI Summary
Perrigo Company plans to release its Q2 2023 financial results on August 8 and will host a conference call. The President and CEO, Patrick Lockwood-Taylor, and CFO Eduardo Bezerra will present at the Canaccord Genuity 43rd Annual Growth Conference on August 9.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
Perrigo Company plc (NYSE: PRGO) announced that the FDA approved Opill®, a progestin-only daily oral contraceptive, for over-the-counter use. Opill® is the first birth control pill available over the counter in the United States. This approval has the potential to transform women's access to contraception.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
conferences
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Stock Data

3.42B
135.92M
0.34%
101.68%
3.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2